DN-1289

Overview

DN-1289 is an orally active and selective inhibitor of dual leucine zipper kinase ( DLK ; IC 50 =17 nM) and leucine zipper-bearing kinase ( LZK ; IC 50 =40 nM). DN-1289 results significant attenuation of optic nerve crush (ONC)-induced p-c-Jun in mice model. DN-1289 has excellent in vivo plasma half-life and blood-brain barrier permeability.

Application

Products | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > JNK

Product Information

• Catalog No.: HY-152142
• CAS No.: 3026597-15-6
• Molecular Formula: C18H19F4N7O2
• Molecular Weight: 441.38
• Purity: 99.63%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution
• Availability: In-stock

Source

Original product source